Ken Griffin Arvinas, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $550 Billion
  • Q2 2025

Call Options

12 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2025

Aug 14, 2025
BUY
$6.07 - $9.62 $242,193 - $383,837
39,900 Added 32.36%
163,200 $1.2 Million
Q1 2025

May 15, 2025
BUY
$7.02 - $20.5 $731,484 - $2.14 Million
104,200 Added 545.55%
123,300 $865,000
Q4 2024

Feb 14, 2025
SELL
$17.83 - $28.04 $135,508 - $213,104
-7,600 Reduced 28.46%
19,100 $366,000
Q3 2024

Nov 14, 2024
SELL
$23.66 - $32.73 $85,176 - $117,827
-3,600 Reduced 11.88%
26,700 $657,000
Q2 2024

Aug 14, 2024
SELL
$24.46 - $40.4 $132,084 - $218,160
-5,400 Reduced 15.13%
30,300 $806,000
Q1 2024

May 15, 2024
BUY
$36.38 - $52.31 $261,936 - $376,632
7,200 Added 25.26%
35,700 $1.47 Million
Q4 2023

Feb 14, 2024
BUY
$14.19 - $42.33 $329,208 - $982,056
23,200 Added 437.74%
28,500 $1.17 Million
Q3 2023

Nov 14, 2023
SELL
$19.64 - $28.21 $365,304 - $524,706
-18,600 Reduced 77.82%
5,300 $104,000
Q2 2023

Aug 14, 2023
BUY
$21.73 - $31.43 $176,013 - $254,583
8,100 Added 51.27%
23,900 $593,000
Q1 2023

May 15, 2023
SELL
$26.15 - $37.26 $73,220 - $104,328
-2,800 Reduced 15.05%
15,800 $431,000
Q4 2022

Feb 14, 2023
SELL
$32.47 - $57.24 $928,642 - $1.64 Million
-28,600 Reduced 60.59%
18,600 $636,000
Q3 2022

Nov 14, 2022
BUY
$41.87 - $57.99 $347,521 - $481,317
8,300 Added 21.34%
47,200 $2.1 Million

Others Institutions Holding ARVN

# of Institutions
245
Shares Held
68.3M
Call Options Held
2.99M
Put Options Held
534K
View Full List

About ARVINAS, INC.

ARVN Quotes by TradingView
  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $361M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email